RxDoctor Payments Data

Heather Doss, MD

Internal Medicine · Liberty, MONPI 1043500275

Payments from drug & device makers

$440in general payments, 2019–2025

Across 26 payments — averaging $16.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$197
  • Genentech USA, Inc.$43
  • Pfizer$38
  • Amgen$38
  • Sanofi-aventis U.S. LLC$37
  • Cranial Technologies, Inc$34
  • plus $53 from 4 others

What the payments were for

  • Food & beverage$440100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$440 in reported general payments places this provider in the 60th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$90,430
Medicare patients
204
Services billed
2,312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide36$55,534
EliquisApixaban49$49,238
TrulicityDulaglutide24$38,087
JardianceEmpagliflozin35$36,426
JanuviaSitagliptin Phosphate72$32,188
RybelsusSemaglutide45$23,831
XareltoRivaroxaban14$20,833
Lantus SolostarInsulin Glargine,hum.Rec.Anlog53$10,393
Spiriva HandihalerTiotropium Bromide16$9,136
Tresiba Flextouch U-100Insulin Degludec13$8,408
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog25$8,359
Cephalexin30$6,918
Atorvastatin Calcium595$6,447
ArexvyRsvpref3 Antigen/As01e/Pf24$6,286
VascepaIcosapent Ethyl106$5,908

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$197$79,36581 claims
PfizerEliquis, Abrysvo$38$54,18565 claims
Lilly USA, LLCTrulicity$11$38,08724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Liberty

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →